{"entity":{"id":"jy232","kind":"drug","name":"JY232","aka":["JY232 Injection"],"tldr":"JY232 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for multiple myeloma.","summary":"JY232 is an in vivo CAR-T (an infusion that makes CAR-T cells inside the body) from Genocury Biotech. The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises. An investigator-initiated, single-centre early phase 1 study (NCT07336823), registered in January 2026, is recruiting. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07336823","url":"https://clinicaltrials.gov/study/NCT07336823"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["genocury-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07336823"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"JY232","modality":"In vivo CAR-T (an infusion that makes CAR-T cells inside the body)","mechanism":"The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jy232/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"genocury-biotech","kind":"company","name":"Genocury Biotech","route":"/companies/genocury-biotech/"}],"trial":[{"id":"nct07336823","kind":"trial","name":"JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07336823/"}]}}